Shen Y, Chen X, Zhang H, Hu H. Long-term cost-effectiveness analysis of onceweekly Semaglutide versus Dulaglutide for the treatment of type 2 diabetes after the renewal of the national drug reimbursement list in China. Health Decision [Internet]. 2024 Jul. 12 [cited 2025 May 2];2(S1). Available from: https://www.hksmp.com/journals/hd/article/view/649